Although no germline mutation of BRCA1 or BRCA2 was identified, the tumor was highly suspected to have a BRCAness phenotype due to the dramatic response to the platinum-based chemotherapy and alterations in ATM and FANCI. Considering the supportive data in pancreatic cancer cell lines, targeting pathways involving homologous recombination may be useful as maintenance therapy in patients with ATM mutation (8). The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.